Aspalathin, a natural product with the potential to reverse hepatic insulin resistance by improving energy metabolism and mitochondrial respiration by Mazibuko-Mbeje, Sithandiwe E. et al.
RESEARCH ARTICLE
Aspalathin, a natural product with the
potential to reverse hepatic insulin resistance
by improving energy metabolism and
mitochondrial respiration
Sithandiwe E. Mazibuko-MbejeID
1,2*, Phiwayinkosi V. DludlaID1,3, Rabia Johnson1,2,
Elizabeth Joubert4,5, Johan Louw2,6, Khanyisani Ziqubu2,6, Luca Tiano3, Sonia Silvestri3,
Patrick Orlando3, Andy R. Opoku6, Christo J. F. Muller1,2,6
1 Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, South
Africa, 2 Division of Medical Physiology, Faculty of Health Sciences, Stellenbosch University, Tygerberg,
South Africa, 3 Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona,
Italy, 4 Plant Bioactives Group, Post-Harvest and Agro-Processing Technologies, Agricultural Research
Council, Infruitec-Nietvoorbij, Stellenbosch, South Africa, 5 Department of Food Science, Stellenbosch
University, Stellenbosch, South Africa, 6 Department of Biochemistry and Microbiology, University of
Zululand, KwaDlangezwa, South Africa
* sithandiwe.mazibuko@mrc.ac.za.
Abstract
Aspalathin is a rooibos flavonoid with established blood glucose lowering properties, how-
ever, its efficacy to moderate complications associated with hepatic insulin resistance is
unknown. To study such effects, C3A liver cells exposed to palmitate were used as a model
of hepatic insulin resistance. These hepatocytes displayed impaired substrate metabolism,
including reduced glucose transport and free fatty acid uptake. These defects included
impaired insulin signaling, evident through reduced phosphatidylinositol-4,5-bisphosphate
3-kinase/ protein kinase B (PI3K/AKT) protein expression, and mitochondrial dysfunction,
depicted by a lower mitochondrial respiration rate. Aspalathin was able to ameliorate these
defects by correcting altered substrate metabolism, improving insulin signaling and mito-
chondrial bioenergetics. Activation of 5´-adenosine monophosphate-activated protein
kinase (AMPK) may be a plausible mechanism by which aspalathin increases hepatic
energy expenditure. Overall, these results encourage further studies assessing the potential
use of aspalathin as a nutraceutical to improve hepatocellular energy expenditure, and
reverse metabolic disease-associated complications.
Introduction
Obesity and dysglycemia, the major characteristic features of the metabolic syndrome, have
become prevalent in the general population and are associated with a rapid rise in morbidity
and mortality [1, 2]. Insulin resistance, mostly driven by an imbalance between intake and uti-
lization of metabolic substrates such as carbohydrates and lipids remains a prominent
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hallmark of the metabolic syndrome [3]. Since described by Randle in 1963 as an important
biochemical mechanism in the development of insulin resistance [4], increasingly research has
focused on effective regulation of glucose and free fatty acid (FFA) metabolism to control dia-
betes and its associated complications [5–9]. Based on these studies, it is now well-accepted
that impaired glucose and FFA metabolism affects optimal functioning of major organs in the
human body, including adipose tissue, skeletal muscle, myocardium and liver. In fact, abnor-
mal substrate metabolism has been correlated with reduced insulin sensitivity and glucose
transport in the liver [10]. The liver plays an essential role in the physiological regulation of
whole-body energy homeostasis and in the pathogenesis of the epidemiologically relevant met-
abolic disorders [11]. Diets rich in saturated fat and sugar content that are increasingly con-
sumed in industrialized and developing societies, together with lack of physical activity
contribute greatly to the development of pathological conditions, such as obesity, hyperten-
sion, insulin resistance, and liver diseases [12]. Through various experimental models, for
example, high fat diet-fed rodents or palmitate exposed hepatocytes, abnormal FFA metabo-
lism has also been linked with defective insulin signaling, mainly through the impairment of
the phosphatidylinositol-4,5-bisphosphate 3-kinase/ protein kinase B (PI3K/AKT) pathway
[10, 13, 14].
Despite the acknowledged importance of the PI3K/AKT pathway in insulin signaling and
cell survival [15], complete mechanisms underlying insulin resistance in the liver are not fully
understood. For instance, 5´-adenosine monophosphate-activated protein kinase (AMPK)
appears to be another instrumental process in controlling cellular energy metabolism, includ-
ing some mechanisms involved in the development of insulin resistance [16, 17]. In the liver,
AMPK may modulate FFA metabolism through the control of mitochondrial function, effects
which can be mediated through coordinated regulation of mitochondrial bioenergetics. As
recently reviewed [18], altered AMPK expression is linked with the development of nonalco-
holic fatty liver disease (NAFLD), a clinical feature that is associated with obesity, insulin resis-
tance, and type 2 diabetes. Consistently, reviewed models also show that liver-specific
inhibition of AMPK is usually followed by reduced mitochondrial content and mitochondrial
respiration indicating that AMPK is important for hepatic mitochondrial function [18, 19].
Thus, it remains of interest to develop novel drugs that act broadly to control energy metabo-
lism, improve mitochondrial function and increase hepatocellular energy expenditure, poten-
tially leading to the reversal of metabolic complications.
Nutraceuticals have garnered a lot of interest for their therapeutic potential in delaying
aging and reducing chronic diseases, with an effort to increase life expectancy [20]. Our group
is exploring the metabolic benefits and potential use of bioactive compounds present in Aspa-
lathus linearis, a South African plant used to manufacture the widely consumed rooibos herbal
tea, as nutraceuticals [21–23]. Of particular interest, is aspalathin (Fig 1A), a C-glucosyl dihy-
drochalcone with blood glucose and lipid lowering properties [24–27]. This flavonoid can
modulate both PI3K/AKT and AMPK pathways to improve substrate metabolism in the adi-
pose tissue, and skeletal and cardiac muscle [8, 27, 28]. Although an aspalathin-enriched green
rooibos extract has displayed moderate effect in improving liver function in an insulin-resis-
tant state [29], currently no study has reported on the impact of aspalathin on the metabolic
syndrome associated hepatic complications. Using palmitate-exposed liver cells as a model of
insulin resistance, we report on the ameliorative effect of aspalathin against altered substrate
metabolism. We further demonstrate that treatment of cells with aspalathin was associated
with improved mitochondrial respiration and enhanced energy expenditure under conditions
of insulin resistance.
Aspalathin reverses palmitate induced hepatic insulin resistance
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Aspalathin (ca 98%, Batch SZI-356-54), synthesized following an already published method by
Han et al. [30], was supplied by High Force Research LTD (Durham, UK). Human C3A liver
cells (ATTC Cat. No. CRL-10741) were from the American Type Culture Collection (Manas-
sas, VA, USA). 2-Deoxy-[3H]-D-glucose and 14C palmitate were obtained from American
Radiolabeled Chemicals (St Louis, MO, USA), while Bradford and RC DC protein assay kits,
and Mini-PROTEAN TGX Stain-Free Precast Gels, nitrocellulose and PVDF membranes were
from Bio-Rad Laboratories (Hercules, CA, USA). Eagle’s Minimum Essential Medium
(EMEM), Dulbecco’s phosphate buffered saline (DPBS, pH 7.4 with calcium and magnesium),
penicillin-streptomycin and MycoAlert mycoplasma detection and ViaLight plus ATP kits
were from Lonza (Basel, Switzerland), while fetal calf serum (FCS) was obtained from Bio-
chrom (Berlin, Germany). Chemiluminescence (ECL) kit was from Amersham Bioscience
(Westborough, MA, USA). Primary antibodies raised against AKT (cat# 9272S), p-AKT
(Ser473) (cat# 9271S), AMPK (cat# 2532), p-AMPK (Thr172) (cat# 2535S), carnitine palmi-
toyltransferase 1A (CPT1) (D3B3) (cat# 12252S), PI3K (cat# 4257S), p-PI3K (p85) (cat#
4228S) were from Cell Signalling Technology (Beverly, MA, USA), while glucose transporter
(GLUT) 2 (cat# ab54460) was from Abcam (Cambridge, UK). The reference control, β-actin,
and secondary antibodies, goatanti-mouse and goatanti-rabbit IgG–horseradish peroxidase,
were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Seahorse XF96 microplate
plates, Seahorse XF Assay media, Seahorse XF base media without phenol red and Seahorse
XF-Cell Mito Stress, Glycolysis stress assay kits were from Agilent (Santa Clare, CA, USA). All
other cell culture reagents were obtained from Sigma-Aldrich (St Louis, MO, USA)
Cell culture and treatment conditions
Hepatocytes (C3A liver cells; Cat. No. CRL-10741) were obtained from the American Type
Culture Collection (Manassas, VA, USA) and cultured in EMEM containing essential amino
acids, sodium pyruvate and L-glutamine. Briefly, cell seeding was done on 24-well plates (55
Fig 1. Chemical structure of aspalathin (A), dose dependent effect of aspalathin on improving glucose uptake (B), and
the effect of insulin and metformin in palmitate-exposed C3A cells (C). Results are expressed as mean ± SEM of three
independent experiments. �� p< 0.01, ��� p< 0.001 versus normal control.
https://doi.org/10.1371/journal.pone.0216172.g001
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000 cells/well) for 2-deoxy-[3H]-D-glucose and 14C palmitate uptake experiments, 96-well
microplates (11 000 cells/well) for ATP and MTT assays and 6-well plates (165 000 cells/well)
for protein analysis. For Seahorse experiments, cells were seeded at 20 000 cells/ well in 96-well
Seahorse microplates until confluent. C3A cells were confirmed to be free from mycoplasma
before successive experiments, using the MycoAlert mycoplasma detection kit according to
the manufacturer’s instructions. Cells were maintained by rinsing with DPBS and trypsiniza-
tion by adding 2 ml trypsin/ versen to the cell culture, and incubation for 3–7 min until cells
dislodged. Thereafter, cells were seeded in EMEM with essential amino acid and L-glutamine
for 5-days and incubated under standard culture conditions at (37˚C in 5% CO2 and humidi-
fied air), and media was changed every 48 hours. Cell passages between 5 and 20 were used for
all experiments. Insulin resistance was induced by exposing C3A liver cells to 0.75 mM palmi-
tate dissolved in EMEM containing 5.5. mM glucose and 2% bovine serum albumin for 16 h,
as previously described [31]. Normal controls were included by culturing in EMEM containing
5.5. mM glucose with 2% bovine serum albumin, but without palmitate. Aspalathin was pre-
pared in dimethyl sulfoxide as previously described [8], and was used at a final concentration
of 10 μM in MEM. Since it can interfere with cell viability in some cultured cells [32], the final
dimethyl sulfoxide concentrations in the media for aspalathin was < 0.001%. The glucose
uptake assay was used to establish optimal concentrations for aspalathin, while insulin and
metformin, both at a dose of 1 μM, were employed for 3 h as controls and to confirm the pal-
mitate model, respectively. After the optimal concentration of aspalathin was established, pal-
mitate-exposed C3A liver cells were serum and glucose starved for 30 min before treatment
with aspalathin (10 μM) and insulin (1 μM) in EMEM without phenol red (to avoid interfer-
ence of phenol red with colorimetric assays) for 3 h under standard tissue culture conditions
(at 37˚C in 5% CO2 and humidified air). Briefly, after 16 h media containing palmitate was
aspirated and DPBS was added for 30 min to cells as it contains no calcium magnesium and no
glucose, so it removes all the chelators from the culture before new treatments are added.
2-Deoxy-[3H]-D-glucose and 14C palmitate uptake assays
2-Deoxy-[3H]-D-glucose and 14C palmitate uptake assays were performed separately, as previ-
ously described [8, 26]. Briefly, after 3-h culture with relevant treatments, cells were exposed
for 3 h under standard tissue culture conditions to 0.5 μCi/mL 2-deoxy-[3H]-D-glucose or
1 μCi/mL 14C palmitate in medium containing aspalathin. Insulin (1 μM), the positive control,
was added during the last 15 min in each experiment. Thereafter, cells were lysed with 0.1 M
NaOH before 2-deoxy-[3H]-D-glucose and 14C palmitate activity in the lysate was assessed by
liquid scintillation (2220 CA, Packard Tri-Carb series, PerkinElmer, Downers Crove, IL,
USA).
Metabolic activity assays
Intracellular ATP was measured using the ViaLight plus ATP kit, following manufacturer’s
recommendations, whereas the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay was done according to a previously described method [33]. For the ATP assay,
luminescence was measured using a BioTek FLX 800 plate reader (BioTek Instruments Inc.,
Winooski, VT, USA), while absorbance as indicator of MTT reduction was detected at 570
nm, using BioTek ELX 800 plate reader. Gen 5 software was used for data acquisition.
Cellular respiration measurements
Oxygen consumption rate (OCR) and extracellular acidification rates (ECAR) were measured
with the Mito Stress assay kit, using the XF96 Extracellular Flux analyzer from Agilent. Briefly,
Aspalathin reverses palmitate induced hepatic insulin resistance
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C3A liver cells were plated into cell culture XF96 microplate plates at 20,000/well for 48 h
before treated as previously described in the cell culture and treatment section. Following
treatment, cells were washed twice with 180 μL of pre-warmed assay medium (XF base
medium supplemented with 10 mM glucose, 2 mM glutamine and 1 mM sodium pyruvate;
pH 7.4), thereafter, cells were incubated in 180 μL XF Assay Medium at 37˚C without CO2 for
60-min to equilibrate temperature and pH prior to OCR. The XF96 plate was then transferred
to a temperature-controlled (37˚C) Seahorse XF96 extracellular flux analyzer where it was sub-
jected to a 10 min equilibration period at three assay cycles, each including a 1 min mix, 3 min
wait and 3 min measure period cycle. Following this, oligomycin (1 μM) was injected in port A
to inhibit ATP synthase. After 3 assay cycles, 75 μM carbonyl cyanide 4 trifluoromethoxy-phe-
nylhydrazone (FCCP) was added in port B to measure maximal respiration. A mixture of
Complex I inhibitor (rotenone) and complex III inhibitor (antimycin) was injected in port C
to shut down mitochondrial respiration and enable the calculation of non-mitochondrial res-
piration. At the end of the incubation period, the plates were used to assess protein concentra-
tion in each well by Bradford protein assay. OCR (pmol/min) was normalized based on
protein content. OCR and ECAR were reported as absolute rates (pmoles/min for OCR and
mpH/min for ECAR).
Glycolysis stress test
After a 3 h incubation with relevant treatment, the medium was changed to assay medium (XF
base medium DMEM without phenol red supplemented with 2 mM glutamine), and cells were
incubated in a non-CO2 incubator at 37˚C for 60 min before the assay. For measurement of
acute glycolysis, the compound of interest (aspalathin) or buffer was injected in port A fol-
lowed by injections of glucose (10 mM), oligomycin (1 μM) and 2-DG (100 mM) into ports B,
C and D, respectively. The instrument was calibrated, and the assay was performed using a gly-
colytic stress test assay protocol as recommended by the manufacturer (Agilent Technologies).
ECAR was measured under basal conditions followed by the sequential addition of aspalathin,
10 mM glucose, 0.5 μM oligomycin, and 100 mM 2-DG (ASP> Glu> Oli> 2-DG). Thereafter
non-glycolytic acidification, glycolysis, glycolytic capacity and glycolytic reserve were calcu-
lated using Wave desktop (Agilent Technologies).
Western blot analysis
A standardized protocol was used for Western blot analysis [34]. Briefly, Mini-PROTEAN
TGX stain-free precast or 10% SDS-PAGE gels were used to separate denatured proteins
(20 or 40 μg) before being transferred to PVDF-P or nitrocellulose membranes. Low-fat
milk powder in Tris-buffered saline (w/v) containing Tween 20 was used to block non-spe-
cific protein labeling. Thereafter, membranes were labeled overnight at 4˚C with relevant
primary antibodies (AKT, p-AKT (Ser473), AMPK, GLUT2, p-AMPK (Thr172), CPT1 and
PI3K, p-PI3K (p85)). The following day, horseradish peroxidase-conjugated secondary
antibody was applied for 1.5 h. Proteins were detected and quantified by chemilumines-
cence using a Chemidoc-XRS imager and Quantity One 1-D software, while molecular
weight band detection was confirmed using ImageJ software (Bio-Rad Laboratories),
respectively. β-actin was used as the reference control. Relevant material for Western blot
analysis, including sources for antibodies used for experimental work and images used for
data quantification, is included as part of the supporting information (S1–S6 Datasets and
S1 Table).
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Statistical analysis
Data are presented as the mean ± SEM of three independent experiments. GraphPad Prism
5 software (GraphPad Software Inc. La Jolla, CA, USA) was used for all statistical analyses.
Comparisons between treatment groups were performed by one-way analysis of variance
(ANOVA), followed by a Tukey post hoc test and Student t-test. A p value of< 0.05 was con-
sidered statistically significant. For cellular respiration experiments, the XF Mito Stress test
report generator and the XF glycolysis stress test report generator automatically calculated
the respective parameters from Wave data that have been exported to Excel. Respiration and
acidification rates are presented as the mean ± SEM of 2 independent experiments in all exper-
iments performed, with 4 to 8 replicate wells in the Seahorse XF96 analyzer. For the experi-
ment of the effect of energy substrates on mitochondrial respiration, the significance level was
determined by performing ANOVA on the complete data set with Tukey׳s post-hoc testing.
The results were considered significant at p< 0.05.
Results
Establishing the effective dose of aspalathin
Glucose uptake assay was used to determine the most active concentration of aspalathin in
C3A liver cells. Results showed that together with both insulin and metformin, all tested con-
centrations of aspalathin (0.0001–100 μM) improved glucose uptake in cells (Fig 1B). How-
ever, a dose of 10 μM was deemed most effective and selected for subsequent experiments (Fig
1C). Furthermore, an insulin resistance model was established by exposing cells with palmitate
before treatment with well-known antidiabetic drugs, insulin and metformin (Fig 1C). This
model was successfully established, as demonstrated by a significant reduction (p< 0.005) in
glucose uptake when compared to cells in the control group (Fig 1C).
Aspalathin improved substrate metabolism in insulin-resistant hepatocytes
Like in many cells, FFAs and glucose are the major substrates utilized by hepatocytes to gener-
ate energy. Impaired hepatic substrate metabolism was confirmed by a significant reduction in
FFA and glucose uptake after palmitate exposure (p < 0.001) (Fig 2A, 2B and 2C). A similar
effect was observed with protein expression of GLUT2 (p< 0.001), the main transporter of
glucose in hepatocytes (Fig 2C). Treatment with aspalathin effectively ameliorated these effects
resulting in increased FFA (p < 0.001), and glucose (p< 0.01) uptake and GLUT2 protein
expression (p< 0.01) (Fig 2A, 2B and 2C). Apart from enhancing GLUT2 expression, insulin
stimulation did not provide a major improvement in FFA and glucose uptake.
Aspalathin moderately improved insulin signaling by regulating PI3K/
AKT pathway in palmitate-exposed hepatocytes
The PI3K/AKT pathway represents one of the most investigated mechanisms in connection
with pathological complications of insulin resistance. Although no changes were observed
under basal conditions, exposure of hepatocytes to elevated palmitate concentrations
reduced phosphorylation of AKT (p < 0.001) in insulin-stimulated cells when compared to
the normal control (Fig 3A). No significant differences were observed for PI3K phosphory-
lation after exposure to palmitate, however, marked difference was seen under insulin-stim-
ulated conditions (Fig 3B). While treatment with aspalathin improved phosphorylation of
PI3K (p < 0.001), that of AKT was only observed under conditions of insulin stimulation
(p < 0.05), in comparison to the insulin resistant group (Fig 3A and 3B).
Aspalathin reverses palmitate induced hepatic insulin resistance
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Aspalathin activated AMPK to regulated FFA oxidation in palmitate-
exposed hepatocytes
Modulation of AMPK, together with CPT1 is increasingly targeted for the regulation of energy
metabolism, especially FFA oxidation. Exposure of hepatocytes to elevated palmitate concen-
trations significantly reduced protein expression of CPT1 (p< 0.001), and slightly enhanced
AMPK (p< 0.001) (Fig 4A and 4B). However, treatment of cells with aspalathin markedly
Fig 3. The effect of aspalathin on protein kinase B (AKT) protein expression (A), and phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K) protein expression (B) in insulin resistant C3A liver cells. Results are expressed as
mean ± SEM of three independent experiments. � p< 0.05, �� p< 0.01, ��� p< 0.001 versus normal control (no
insulin); # p< 0.05, ### p< 0.001 versus palmitate control (no insulin).
https://doi.org/10.1371/journal.pone.0216172.g003
Fig 2. The effect of aspalathin on glucose uptake (A), glucose 2 protein expression (B), and palmitate uptake (C) in
insulin resistant C3A liver cells. Results are expressed as mean ± SEM of three independent experiments. � p< 0.05, ��
p< 0.01, ��� p< 0.001 versus normal control (no insulin); # p< 0.05, ## p< 0.01, ### p< 0.001 versus palmitate
control (no insulin).
https://doi.org/10.1371/journal.pone.0216172.g002
Aspalathin reverses palmitate induced hepatic insulin resistance
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upregulated the expression of both proteins (both p< 0.001). Insulin stimulation only had an
effect in further enhancing CPT1 expression with aspalathin treatment (Fig 4A).
Aspalathin enhanced metabolic activity in palmitate-exposed hepatocytes
The MTT and ATP monitoring assays are widely used to measure the metabolic activity of via-
ble cells. While no effect was observed after cells were exposed to high palmitate concentra-
tions with MTT assay, ATP production was significantly reduced (p< 0.01) when compared
to the control (Fig 5A and 5B). However, aspalathin treatment improved metabolic activity of
cells. Furthermore, it was evident that insulin stimulation did not affect metabolic activity.
Aspalathin improves mitochondrial respiration in palmitate-exposed
hepatocytes
Mitochondrial respiration was measured through chronological injections of oligomycin,
FCCP, antimycin A and rotenone to assess basal respiration, ATP production, proton leak,
Fig 4. The effect of aspalathin on carnitine palmitoyltransferase 1 (CPT1) protein expression (A), and AMP-activated
protein kinase (AMPK) protein expression (B) in palmitate exposed C3A cells. Results are expressed as mean ± SEM of
three independent experiments. � p< 0.05, �� p< 0.01, ��� p< 0.001 versus normal control (no insulin); # p< 0.05, ##
p< 0.01, ### p< 0.001 versus palmitate control (no insulin).
https://doi.org/10.1371/journal.pone.0216172.g004
Fig 5. The effect of aspalathin on metabolic activity in insulin-resistant C3A liver cells, as measured by assessing MTT
activity (A) and ATP production (B), respectively. Results are expressed as mean ± SEM of three independent
experiments. � p< 0.05, �� p< 0.01 versus vehicle normal control (no insulin); # p< 0.05, ### p< 0.001 versus
palmitate control (no insulin).
https://doi.org/10.1371/journal.pone.0216172.g005
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maximal respiration, spare respiratory capacity, and non-mitochondrial respiration (Fig 6A–
6F). Combined results of OCR after treatment with or without palmitate and aspalathin are
shown in Fig 6A and 6B, with individual parameters depicted in Fig 6C–6F. In terms of basal
OCR, palmitate significantly reduced both basal and insulin-stimulated OCR (p< 0.0001)
when compared to control cells, confirming the high degree of insulin resistance in these cells
(Fig 6A and 6B). In agreement with our metabolic assay (Fig 5B), palmitate reduced ATP pro-
duction (p< 0.0001) (Fig 6D), in maximal respiration (Fig 6E) and spare respiratory capacity
(Fig 6F). However, aspalathin treatment significantly reversed these effects, thereby enhancing
ATP production and basal, maximal and spare capacity respiration (Fig 6C–6F). The observed
effect of aspalathin was comparable to that of the positive control (insulin). In terms of ECAR,
palmitate treatment reduced glycolysis, but this reduction was ameliorated by aspalathin treat-
ment with or without insulin (Fig 6F).
Aspalathin improves glycolytic rate in palmitate-exposed hepatocytes
The rate of glucose conversion into pyruvate (glycolysis) was determined after injecting with
or without aspalathin in port A, (Fig 7B). Albeit not significant, palmitate reduced glycolysis
rate and this slight reduction was reversed to that of the normal control in the aspalathin
treated group (Fig 7C). However, conclusions cannot be drawn from this effect, since the effect
was not significant. Glycolytic capacity, the measurement for maximum rate of conversion of
glucose to lactate by cells showed that palmitate treatment reduced glycolytic capacity
Fig 6. The effects of aspalathin on mitochondrial respiration in insulin-resistant C3A liver cells. The graph shows
oxygen consumption rate of all treatments (OCR) (A), individual parameters for basal respiration (B), ATP production
(C), maximal respiration (D), and spare respiratory capacity (E), and extracellular acidification rates (F). Oxygen
consumption rate was measured under basal conditions followed by the sequential injection of oligomycin (1 μM),
FCCP (0.75 μM), as well as rotenone (0.5 μM) & antimycin A (0.5 μM), as indicated. Each data point represents an
OCR measurement. Data are expressed as means ± SEM, n = 2 independent experiments. ���� p< 0.0001 versus
normal (no insulin) control, #### p< 0.0001 versus palmitate control.
https://doi.org/10.1371/journal.pone.0216172.g006
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(p< 0.001). This reduction was attenuated in cells treated with palmitate and aspalathin
(p< 0.001) (Fig 7D). Glycolytic reserve was calculated to determine the capability of a cell to
respond to an energetic demand, and palmitate-treated cells showed inability to respond to
energy demands, while treatment with aspalathin enhanced glycolytic reserve (p< 0.001) (Fig
7E). Insulin stimulation did not further improve the basal effects of aspalathin.
Discussion
The rapid rise in deaths due to noncommunicable diseases warrants further investigation into
novel drugs that can act broadly to alter energy metabolism or influence pathways that con-
tribute to metabolic disease-associated complications. Hepatocytes play a major role in regu-
lating energy metabolism, in addition to their established function in the detoxification of
metabolites and synthesis of proteins. Abnormal hepatic energy metabolism has been associ-
ated with the development of various metabolic complications, including NAFLD, insulin
resistance, and diabetes mellitus [7, 14, 35]. C3A cells are known to exhibit many liver-specific
features, including gluconeogenesis and glycogen synthesis in response to insulin stimulation.
These cells also express GLUT2 and produce lipid intermediates such as cholesterol [35]. On
the other hand, exposure to high palmitate concentrations has been successfully used to set up
models of insulin resistance in many cell types, including C3A liver cells [8, 14, 31]. To date,
studies reporting on the therapeutic potential of aspalathin against liver associated metabolic
complications are lacking. The current study tested the beneficial effects of aspalathin against
palmitate-induced hepatic insulin resistance using C3A cells.
Fig 7. Extracellular acidification rates (ECAR) response of C3A liver cells to aspalathin (10 μM), glucose (10 mM),
oligomycin (1 μM) and 2-deoxyglucose (2-DG) (100 mM), respectively (A). Individual parameters for glycolysis,
glycolytic capacity, glycolytic reserve of C3A liver cells after aspalathin treatment (B and C), and the effect of palmitate
and aspalathin on OCAR/ECAR (D). ECAR was measured under basal conditions followed by the sequential addition
of aspalathin (10 μM), glucose (10 mM), oligomycin (1 μM), and 2-deoxyglucose (2-DG) (100 mM) the order was as
follows (aspalathin>Glu> Oli> 2-DG). Data are expressed as means ± SEM, n = 3 independent experiments. ����
p< 0.0001 versus normal (no insulin) control, #### p< 0.0001 versus palmitate control.
https://doi.org/10.1371/journal.pone.0216172.g007
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Exposing C3A cells to high palmitate concentrations led to a number of metabolic and cel-
lular signaling abnormalities that are related to the development of insulin resistance. Such
abnormalities included altered substrate metabolism, mainly characterized by suppressed glu-
cose and FFA uptake, as well as reduced GLUT2 expression, occurring concomitant to altered
insulin signaling. Reduced phosphorylation of both PI3K and AKT could explain impaired
insulin signaling and development of insulin resistance, as previously demonstrated [8, 13,
31]. Down-regulated expression of CPT1, which is required for mitochondrial FFA uptake,
could explain malfunctioning β-oxidation and obstructed energy metabolism. In any case,
mitochondria are the main site for lipid oxidation and a connection between reduced FFA
uptake, as well as diminished ATP production and compromised respiratory chain function
has been previously reported [14, 36]. In agreement, the current study showed that palmitate
insult not only impaired substrate metabolism, but also suppressed the glycolytic rate and
altered mitochondrial bioenergetics, which could have caused depletion in ATP production.
Both glycolysis and mitochondrial respiration reactions are known to be responsible for the
major production of ATP in mammals [37]. Therefore, as recently reviewed [18], regulating
mitochondrial respiration to increase hepatic energy expenditure, along with improving insu-
lin sensitivity, could be an effective strategy to curb complications associated with the meta-
bolic syndrome, including insulin resistance.
The major findings in this paper suggest that aspalathin can provide a number of beneficial
effects that are essential in ameliorating hepatic-induced insulin resistance. Such benefits
include tight regulation of hepatic substrate metabolism, which could have led to improved
insulin signaling and mitochondrial bioenergetics. As reported by our group and others in dif-
ferent tissue types [8, 27, 28, 31], the modulatory effect of PI3K/AKT as well as AMPK path-
ways, could be a possible mechanism by which this phytochemical improves insulin signaling
and enhance hepatic energy expenditure. Apparently, some of the commonly used diabetic
drugs such as insulin and metformin are also known to induce their therapeutic effects
through the modulatory effect of PI3K/AKT and AMPK pathways, resulting in improved sub-
strate metabolism and insulin signaling [35, 38]. Similarly, natural products like resveratrol or
magnolol can modulate AMPK activity to inhibit lipid-induced toxicity in liver cells [39, 40].
Recent evidence also shows that celastrol, a tripterine isolated from the root extracts of Tripter-
ygium wilfordii plant, could ameliorate hepatic insulin resistance by improving insulin signal-
ing and mitochondrial function [41]. Similar to these compounds, Ulicná and colleagues
recently showed that rooibos attenuates carbon tetrachloride-induced-induced injury to mito-
chondrial respiratory function and energy production in rat liver [42]. Whereas, Hattingh and
co-workers found that activation of AMPK was necessary for amelioration of ethidium bro-
mide induced mitochondrial dysfunction in 3T3-L1 adipocytes [43]. Thus, we hypothesize
that aspalathin, in addition to improving insulin signaling, is likely to target the mitochon-
drion to increase energy expenditure and reverse insulin resistance. These effects can poten-
tially lead to the amelioration of metabolic syndrome associated complications, including
inflammation and oxidative stress. Although not investigated in the current study, existing evi-
dence shows that aspalathin or an aspalathin-enriched enriched rooibos extract can counteract
oxidative stress under conditions of metabolic dysregulation in the liver [44–46]. However,
this study demonstrated that aspalathin showed limited activity to enhance insulin-sensitizing
effects in vitro. This result is consistent with our recent findings [29], showing that a rooibos
extract containing high levels of aspalathin displayed an ameliorative effect when used in com-
bination with insulin to reverse palmitate-induced hepatic insulin resistance. Nonetheless,
additional work, especially an investigation of transcriptional factors involved in mitochon-
drial bioenergetics, is necessary to support such a hypothesis. This includes mechanistic stud-
ies, either making use of genetically mutated rodents or gene-specific silencing in vitro, can be
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essential tools in establishing the involvement of PI3K/AKT or AMPK in the therapeutic effect
of aspalathin.
Conclusion
This study showed that aspalathin can target the liver cells to regulate hepatic cellular metabo-
lism and increase energy expenditure likely by modulating PI3K/AKT and AMPK signaling
pathways. However, before proposals presented in this study are accepted, several issues need
to be resolved first. This includes confirming these results in an established in vivo model of
insulin resistance. Such information would not only improve our current understanding on
the mechanisms involved in metabolic disease associated liver dysfunction, but would also
highlight the potential use of aspalathin as a nutraceutical to protect against metabolic disease-
related complications.
Supporting information
S1 Dataset. Original Western blot picture of glucose transporter (GLUT) 2, experiment 1(A),
experiment 2(B), experiment 3 (C) and representative cropped blot (D). C3A liver cells were
cultured in EMEM supplemented with 8 mM glucose with or without 0.75 mM palmitate for
16 h, and then treated with aspalathin 10 μM for 3 h. Insulin (1 μM) was added during the last
15 min and used as a positive control. Cells were lysed and subjected to Western blot analyses.
All 3 independent experiments were analysed and one representative blot was cropped to be
included in the article. Results are from three independent experiments. Please note: G-repre-
sents “normal control”, GI is “normal control+ insulin”, P is “palmitate control”, PI is “palmi-
tate+insulin”, GRE is “green rooibos extract”, GRE+I is “green rooibos extract + insulin”, ASP
is “aspalathin”, and ASP+I is “aspalathin+ insulin”.
(DOCX)
S2 Dataset. Original Western blot picture of phosphor-protein kinase B (pAKT) and total-
protein kinase B (tAKT), experiment 1 (A, B), experiment 2 (C, D), experiment 3 (E, F) and
cropped blot (G). C3A liver cells were cultured in EMEM supplemented with 8 mM glucose
with or without 0.75 mM palmitate (Pal) for 16 h, thereafter treated with aspalathin 10 μM for
3 h. Insulin (1 μM) was added during the last 15 min and used as a positive control. Cells were
lysed and subjected to Western blot analyses. After probing with pAKT blots were stripped
and probed with tAKT. The % of pAKT/tAKT, was used to estimate the level of AKT (Ser
473). All 3 independent experiments were analysed and one representative blot was cropped to
be included in the article. Results are from three independent experiments. Please note: G-rep-
resents “normal control”, GI is “normal control+ insulin”, P is “palmitate control”, PI is “pal-
mitate+insulin”, GRE is “green rooibos extract”, GRE+I is “green rooibos extract + insulin”,
ASP is “aspalathin”, and ASP+I is “aspalathin+ insulin”.
(DOCX)
S3 Dataset. Original Western blot picture for phosphor-phosphoinositide 3-kinase (pPI3K)
and total-phosphoinositide 3-kinase (tPI3K), experiment 1 (A, B), experiment 2 (C, D), experi-
ment 3 (E, F) and cropped blot (G). C3A liver cells were cultured in EMEM supplemented
with 8 mM glucose with or without 0.75 mM palmitate (Pal) for 16 h, thereafter treated with
aspalathin 10 μM for 3 h. Insulin (1 μM) was added during the last 15 min and used as a posi-
tive control. Cells were lysed and subjected to Western blot analyses. After probing with
pPI3K blots were stripped and probed with tPI3K. The % of pPI3K/tPI3K, was used to estimate
the level of PI3K (p85). All 3 independent experiments were analysed and one representative
blot was cropped to be included in the article. Results are from three independent experiments.
Aspalathin reverses palmitate induced hepatic insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0216172 May 2, 2019 12 / 16
Please note: G-represents “normal control”, GI is “normal control+ insulin”, P is “palmitate
control”, PI is “palmitate+insulin”, GRE is “green rooibos extract”, GRE+I is “green rooibos
extract + insulin”, ASP is “aspalathin”, and ASP+I is “aspalathin+ insulin”.
(DOCX)
S4 Dataset. Original Western blot picture of carnitine palmitoyltransferase 1 (CPT1), experi-
ment 1(A), experiment 2(B), experiment 3 (C) and cropped blot (D). C3A liver cells were cul-
tured in EMEM supplemented with 8 mM glucose with or without 0.75 mM palmitate (Pal)
for 16 h, and then treated with aspalathin 10 μM for 3 h. Insulin (1 μM) was added during the
last 15 min and used as a positive control. Cells were lysed and subjected to Western blot anal-
yses. All 3 independent experiments were analysed and one representative blot was cropped to
be included in the article. Results are from three independent experiments. Please note: G-rep-
resents “normal control”, GI is “normal control+ insulin”, P is “palmitate control”, PI is “pal-
mitate+insulin”, GRE is “green rooibos extract”, GRE+I is “green rooibos extract + insulin”,
ASP is “aspalathin”, and ASP+I is “aspalathin+ insulin”.
(DOCX)
S5 Dataset. Original Western blot picture of phosphor-AMP-activated protein kinase
(pAMPK) and total-AMP-activated protein kinase (tAMPK), experiment 1 (A, B), experiment
2 (C, D), experiment 3 (E, F) and cropped blot (G). C3A liver cells were cultured in EMEM
supplemented with 8 mM glucose with or without 0.75 mM palmitate (Pal) for 16 h, thereafter
treated with aspalathin 10 μM for 3 h. Insulin (1 μM) was added during the last 15 min and
used as a positive control. Cells were lysed and subjected to Western blot analyses. After prob-
ing with pAMPK blots were stripped and probed with tAMPK. The % of pAMPK/tAMPK,
was used to estimate the level of AMPK (Thr172). All 3 independent experiments were ana-
lysed and one representative blot was cropped to be included in the article. Results are from
three independent experiments. Please note: G-represents “normal control”, GI is “normal
control+ insulin”, P is “palmitate control”, PI is “palmitate+insulin”, GRE is “green rooibos
extract”, GRE+I is “green rooibos extract + insulin”, ASP is “aspalathin”, and ASP+I is “aspa-
lathin+ insulin”.
(DOCX)
S6 Dataset. Raw experimental data.
(XLSX)
S1 Table. List of antibodies and relevant dilutions used in the current study.
(DOCX)
Author Contributions
Conceptualization: Sithandiwe E. Mazibuko-Mbeje, Phiwayinkosi V. Dludla, Elizabeth Jou-
bert, Johan Louw, Sonia Silvestri, Andy R. Opoku, Christo J. F. Muller.
Data curation: Sithandiwe E. Mazibuko-Mbeje, Khanyisani Ziqubu.
Formal analysis: Sithandiwe E. Mazibuko-Mbeje, Phiwayinkosi V. Dludla, Rabia Johnson,
Khanyisani Ziqubu.
Funding acquisition: Sithandiwe E. Mazibuko-Mbeje, Elizabeth Joubert, Johan Louw, Christo
J. F. Muller.
Investigation: Sithandiwe E. Mazibuko-Mbeje, Rabia Johnson, Khanyisani Ziqubu.
Aspalathin reverses palmitate induced hepatic insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0216172 May 2, 2019 13 / 16
Methodology: Phiwayinkosi V. Dludla, Rabia Johnson, Khanyisani Ziqubu, Luca Tiano, Sonia
Silvestri, Patrick Orlando, Christo J. F. Muller.
Resources: Sithandiwe E. Mazibuko-Mbeje, Elizabeth Joubert, Johan Louw, Andy R. Opoku,
Christo J. F. Muller.
Supervision: Elizabeth Joubert, Johan Louw, Andy R. Opoku, Christo J. F. Muller.
Validation: Luca Tiano, Sonia Silvestri, Patrick Orlando, Christo J. F. Muller.
Writing – original draft: Sithandiwe E. Mazibuko-Mbeje, Phiwayinkosi V. Dludla, Luca
Tiano, Sonia Silvestri, Patrick Orlando, Christo J. F. Muller.
Writing – review & editing: Sithandiwe E. Mazibuko-Mbeje, Phiwayinkosi V. Dludla, Rabia
Johnson, Elizabeth Joubert, Johan Louw, Khanyisani Ziqubu, Luca Tiano, Sonia Silvestri,
Patrick Orlando, Andy R. Opoku, Christo J. F. Muller.
References
1. International Diabetes Federation. IDF Diabetes Atlas, eighth edition 2017. Available at http://
diabetesatlas.org/resources/2017-atlas.html, Accessed 25 September 2018.
2. Obesity 2015 Collaborators GBD, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health
Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1):13–27.
https://doi.org/10.1056/NEJMoa1614362 PMID: 28604169
3. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes
and modification by exercise training. Compr Physiol. 2013; 3(1):1–58. https://doi.org/10.1002/cphy.
c110062 PMID: 23720280
4. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sen-
sitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1(7285):785–789. PMID:
13990765
5. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, et al. Glucose and free fatty
acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resis-
tance. J Clin Invest. 1989; 84(1):205–213. https://doi.org/10.1172/JCI114142 PMID: 2661589
6. Perry RJ, Wang Y, Cline GW, Rabin-Court A, Song JD, Dufour S, et al. Leptin mediates a glucose-fatty
acid cycle to maintain glucose homeostasis in starvation. Cell. 2018; 172(1–2):234–248.e217. https://
doi.org/10.1016/j.cell.2017.12.001 PMID: 29307489
7. Kim KH, Choi S, Zhou Y, Kim EY, Lee JM, Saha PK, et al. Hepatic FXR/SHP axis modulates systemic
glucose and fatty acid homeostasis in aged mice. Hepatology. 2017; 66(2):498–509. https://doi.org/10.
1002/hep.29199 PMID: 28378930
8. Mazibuko SE, Joubert E, Johnson R, Louw J, Opoku AR, Muller CJ. Aspalathin improves glucose and
lipid metabolism in 3T3-L1 adipocytes exposed to palmitate. Mol Nutr Food Res. 2015; 59(11):2199–
2208. https://doi.org/10.1002/mnfr.201500258 PMID: 26310822
9. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lan-
cet. 1994; 343(8890):155–158. PMID: 7904009
10. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, et al. Loss of insulin signal-
ing in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell.
2000; 6(1):87–97. PMID: 10949030
11. Nakagawa Y, Satoh A, Yabe S, Furusawa M, Tokushige N, Tezuka H, et al. Hepatic CREB3L3 controls
whole-body energy homeostasis and improves obesity and diabetes. Endocrinology. 2014; 155
(12):4706–4719. https://doi.org/10.1210/en.2014-1113 PMID: 25233440
12. Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J
Investig Med. 2017; 65(8):1102–1115. https://doi.org/10.1136/jim-2017-000524 PMID: 28947639
13. Titchenell PM, Quinn WJ, Lu M, Chu Q, Lu W, Li C, et al. Direct hepatocyte insulin signaling is required
for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab. 2016; 23
(6):1154–1166. https://doi.org/10.1016/j.cmet.2016.04.022 PMID: 27238637
14. Abu Bakar MH, Sarmidi MR, Tan JS, Mohamad Rosdi MN. Celastrol attenuates mitochondrial dysfunc-
tion and inflammation in palmitate-mediated insulin resistance in C3A hepatocytes. Eur J Pharmacol.
2017; 799:73–83. https://doi.org/10.1016/j.ejphar.2017.01.043 PMID: 28161417
Aspalathin reverses palmitate induced hepatic insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0216172 May 2, 2019 14 / 16
15. Manning BD, Toker A. AKT/PKB Signaling: Navigating the network. Cell. 2017; 169(3):381–405.
https://doi.org/10.1016/j.cell.2017.04.001 PMID: 28431241
16. Day EA, Ford RJ, Steinberg GR. AMPK as a therapeutic target for treating metabolic diseases. Trends
Endocrinol Metab. 2017; 28(8):545–560. https://doi.org/10.1016/j.tem.2017.05.004 PMID: 28647324
17. Rabinovitch RC, Samborska B, Faubert B, Ma EH, Gravel SP, Andrzejewski S, et al. AMPK maintains
cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. Cell Rep.
2017; 21(1):1–9. https://doi.org/10.1016/j.celrep.2017.09.026 PMID: 28978464
18. Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases.
Cell Metab. 2018; 27(1):22–41. https://doi.org/10.1016/j.cmet.2017.08.002 PMID: 28867301
19. Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and
potential new treatments. Nutrients. 2017; 9(4). https://doi.org/10.3390/nu9040387 PMID: 28420094
20. Nasri H, Baradaran A, Shirzad H, Rafieian-Kopaei M. New concepts in nutraceuticals as alternative for
pharmaceuticals. Int J Prev Med. 2014; 5(12):1487–1499. PMID: 25709784
21. Johnson R, de Beer D, Dludla PV, Ferreira D, Muller CJF, Joubert E. Aspalathin from rooibos (Aspa-
lathus linearis): a bioactive C-glucosyl dihydrochalcone with potential to target the metabolic syndrome.
Planta Med. 2018; 84(9–10):568–583. https://doi.org/10.1055/s-0044-100622 PMID: 29388183
22. Muller CJ, Malherbe CJ, Chellan N, Yagasaki K, Miura Y, Joubert E. Potential of rooibos, its major C-
glucosyl flavonoids and z-2-(beta-D-glucopyranoloxy)-3-phenylpropenoic acid in prevention of meta-
bolic syndrome. Crit Rev Food Sci Nutr. 2018; 58(2):227–246. https://doi.org/10.1080/10408398.2016.
1157568 PMID: 27305453
23. Joubert E, de Beer D. Rooibos (Aspalathus linearis) beyond the farm gate: from herbal tea to potential
phytopharmaceutical. S Afr J Bot. 2011; 77(4):869–886.
24. Johnson R, Dludla PV, Muller CJ, Huisamen B, Essop MF, Louw J. The transcription profile unveils the
cardioprotective effect of aspalathin against lipid toxicity in an in vitro H9c2 model. Molecules. 2017; 22
(2). https://doi.org/10.3390/molecules22020219 PMID: 28146135
25. Kawano A, Nakamura H, Hata S, Minakawa M, Miura Y, Yagasaki K. Hypoglycemic effect of aspalathin,
a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine.
2009; 16(5):437–443. https://doi.org/10.1016/j.phymed.2008.11.009 PMID: 19188054
26. Muller CJ, Joubert E, de Beer D, Sanderson M, Malherbe CJ, Fey SJ, et al. Acute assessment of an
aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential. Phytome-
dicine. 2012; 20(1):32–39. https://doi.org/10.1016/j.phymed.2012.09.010 PMID: 23083813
27. Son MJ, Minakawa M, Miura Y, Yagasaki K. Aspalathin improves hyperglycemia and glucose intoler-
ance in obese diabetic ob/ob mice. Eur J Nutr. 2013; 52(6):1607–1619. https://doi.org/10.1007/
s00394-012-0466-6 PMID: 23238530
28. Johnson R, Dludla P, Joubert E, February F, Mazibuko S, Ghoor S, et al. Aspalathin, a dihydrochalcone
C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference
and apoptosis. Mol Nutr Food Res. 2016; 60(4):922–934. https://doi.org/10.1002/mnfr.201500656
PMID: 26773306
29. Mazibuko-Mbeje SE, Dludla PV, Roux C, Johnson R, Ghoor S, Joubert E, et al. Aspalathin-enriched
green rooibos extract reduces hepatic insulin resistance by modulating PI3K/AKT and AMPK pathways.
Int J Mol Sci. 2019; 20(3). https://doi.org/10.3390/ijms20030633 PMID: 30717198
30. Han Z, Achilonu MC, Kendrekar PS, Joubert E, Ferreira D, Bonnet SL, et al. Concise and scalable syn-
thesis of aspalathin, a powerful plasma sugar-lowering natural product. J Nat Prod. 2014; 77(3):583–
588. https://doi.org/10.1021/np4008443 PMID: 24354397
31. Mazibuko SE, Muller CJ, Joubert E, de Beer D, Johnson R, Opoku AR, et al. Amelioration of palmitate-
induced insulin resistance in C(2)C(1)(2) muscle cells by rooibos (Aspalathus linearis). Phytomedicine.
2013; 20(10): 813–819. https://doi.org/10.1016/j.phymed.2013.03.018 PMID: 23639187
32. Dludla PV, Jack B, Viraragavan A, Pheiffer C, Johnson R, Louw J, et al. A dose-dependent effect of
dimethyl sulfoxide on lipid content, cell viability and oxidative stress in 3T3-L1 adipocytes. Toxicol Rep.
2018; 4; 5:1014–1020.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 1983; 65(1–2):55–63. PMID: 6606682
34. Mahmood T, Yang PC. Western blot: technique, theory, and trouble shooting. N Am J Med Sci. 2012; 4
(9):429–434. https://doi.org/10.4103/1947-2714.100998 PMID: 23050259
35. Rui L. Energy metabolism in the liver. Compr Physiol. 2014; 4(1):177–197. https://doi.org/10.1002/
cphy.c130024 PMID: 24692138
36. Raffaella C, Francesca B, Italia F, Marina P, Giovanna L, Susanna I. Alterations in hepatic mitochondrial
compartment in a model of obesity and insulin resistance. Obesity (Silver Spring, Md). 2008; 16
(5):958–964.
Aspalathin reverses palmitate induced hepatic insulin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0216172 May 2, 2019 15 / 16
37. Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mam-
mals. Physiol Rev. 1997; 77(3):731–758. https://doi.org/10.1152/physrev.1997.77.3.731 PMID:
9234964
38. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, et al. Metformin and insulin suppress hepatic
gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137(4):635–646.
https://doi.org/10.1016/j.cell.2009.03.016 PMID: 19450513
39. Tian Y, Feng H, Han L, Wu L, Lv H, Shen B, et al. Magnolol alleviates inflammatory responses and lipid
accumulation by AMP-activated protein kinase-dependent peroxisome proliferator-activated receptor
alpha activation. Front Immunol. 2018; 9:147. https://doi.org/10.3389/fimmu.2018.00147 PMID:
29467759
40. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver dis-
ease by activating AMP-activated protein kinase. Acta Pharmacol Sin. 2008; 29(6):698–706. https://
doi.org/10.1111/j.1745-7254.2008.00807.x PMID: 18501116
41. Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell.
2015; 161(5):999–1011. https://doi.org/10.1016/j.cell.2015.05.011 PMID: 26000480
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